These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33681308)

  • 1. Hypertension and COVID-19: Ongoing Controversies.
    Tadic M; Saeed S; Grassi G; Taddei S; Mancia G; Cuspidi C
    Front Cardiovasc Med; 2021; 8():639222. PubMed ID: 33681308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
    Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
    PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan.
    Yoshihara F; Ohtsu H; Nakai M; Tsuzuki S; Hayakawa K; Terada M; Matsunaga N; Yasuda S; Ogawa H; Ohmagari N
    J Cardiol; 2022 Oct; 80(4):292-297. PubMed ID: 35469713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
    Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
    J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease.
    ElAbd R; AlTarrah D; AlYouha S; Bastaki H; Almazeedi S; Al-Haddad M; Jamal M; AlSabah S
    Front Med (Lausanne); 2021; 8():600385. PubMed ID: 33748156
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
    Kuzeytemiz M; Tenekecioglu E
    J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
    Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
    Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
    Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
    Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
    Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
    PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
    Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
    Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
    Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
    Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19.
    Kang SH; Lee DH; Han KD; Jung JH; Park SH; Dai AM; Wei HG; Yoon CH; Youn TJ; Chae IH; Kim CH
    Clin Hypertens; 2021 Jun; 27(1):11. PubMed ID: 34059140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis.
    Liu X; Long C; Xiong Q; Chen C; Ma J; Su Y; Hong K
    Clin Cardiol; 2020 Aug; ():. PubMed ID: 32757246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension.
    Ma J; Shi X; Yu J; Lv F; Wu J; Sheng X; Pan Q; Yang J; Cao H; Li L
    Front Cardiovasc Med; 2021; 8():577398. PubMed ID: 34136537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.